Alumkal, Joshi
| Bagby, Grover C.
| Bascom, Paul
| Beer, Tomasz M.
| Blanke, Charles D.
| Chui, Stephen
| Deininger, Michael WN
| DeLoughery, Thomas
| Druker, Brian J.
| Epner, Elliot
| Fleming, William H.
| Fromme, Erik
| Greenberg, Daniel
| Hayes-Lattin, Brandon
| Heinrich, Michael C.
| Kemmer, Kathleen
| Kovacsovics, Tibor
| Lopez, Charles D.
| Luoh, Shiuh-Wen
| Mauro, Michael J.
| Maziarz, Richard
| Meyers, Gabrielle
| Okada, Craig
| Ryan, Christopher W.
| Sanborn, Rachel E
| Skach, William
| Streeter, Philip
| Sullivan, Richard
| Thomas, Charles
| | Webster, Devon | |
|
|
|
 |
|
|
Our Faculty Christopher W. Ryan
Associate Professor of Medicine
Interim Associate Director for Clinical Research, OHSU Cancer Institute Specialty: Medical Oncology, Sarcoma and Genitourinary
Clinic Phone: 503-494-6594
E-mail: ryanc@ohsu.edu
Dr. Ryan received his M.D. from the State University of New York Health Science Center in Syracuse, NY. He completed his residency and fellowship in Hematology/Oncology at the University of Chicago, where he remained on faculty prior to joining OHSU in 2003. Dr. Ryan specializes in the treatment of genitourinary cancers and sarcomas. His research focuses on clinical trial development of new agents for kidney cancer, prostate cancer, and sarcoma. He has particular interest in development of targeted drugs for kidney cancer, management of bone complications of prostate cancer, and multidisciplinary treatment of high-risk soft tissue sarcomas.
Appointments
- Associate Professor, Department of Medicine, Hematology/Oncology
- Interim Associate Director for Clinical Research, OHSU Cancer Institute
|
|
Professional Education and Training
- Cornell University, BA Cell Biology 1985-1989
- SUNY Health Science Center at Syracuse, Syracuse, NY, M.D., 1994
- University of Chicago, Internal Medicine Residency 1994-1997
- University of Chicago, Medical Oncology Fellowship 1997-2000
| |
|  |
|
Selected Publications
- Ryan CW, Stadler WM, Vogelzang NJ. A Phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. BJU Int. 2005;95:263-8.
- Ryan CW, Vogelzang NJ, Vokes EE, Kindler HL, Undevia SD, Humerickhouse R, Andr? AK, Wang Q. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res 2004;10:4406-11.
- Ryan CW, Vogelzang NJ, Stadler WM. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-? in patients with metastatic renal cell cancer. Cancer 2002;94:2602-2609.
- Ryan CW, Vokes EE, Vogelzang NJ, Janisch L, Kobayashi K, Ratain MJ. A phase I study of suramin with once or twice monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002;50:1-5.
- Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM: GM-CSF in combination immunotherapy for metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer 2000; 88:1317-1324.
|
|
